nach oben

Current Hypertension Reports

Erschienen in:

01.08.2020 | Preeclampsia (VD Garovic, Section Editor)

Postpartum Hypertension

verfasst von: V. Katsi, G. Skalis, G. Vamvakou, D. Tousoulis, T. Makris

Erschienen in: Current Hypertension Reports | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hypertension affects approximately 10% of pregnancies and may persist in the postpartum period. Furthermore, de novo hypertension may present after delivery, but its exact prevalence is not verified. Both types of hypertension expose the mother to eventually severe complications like eclampsia, stroke, pulmonary edema, and HELLP (hemolysis, elevated liver enzymes, low platelet) syndrome.

Recent Findings

Until today, there are limited data regarding the risk factors, pathogenesis, and pathophysiology of postpartum hypertensive disorders. However, there is certain evidence that preeclampsia may in large part be responsible. Women who experienced preeclampsia during pregnancy, although considered cured after delivery and elimination of the placenta, continue to present endothelial and renal dysfunction in the postpartum period. The brain and kidneys are particularly sensitive to this pathological vascular condition, and severe complications may result from their involvement.

Summary

Large randomized trials are needed to give us the evidence that will allow a timely diagnosis and treatment. Until then, medical providers should increase their knowledge regarding hypertension after delivery because many times there is an underestimation of the complications that can ensue after a misdiagnosed or undertreated postpartum hypertension.

American College of Obstetricians and Gynecologists: TaskForce on Hypertension in Pregnancy.Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31.

Goel A, Maski M, Baijracharva S, Wenger J, Zhang D,Salahuddin S. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation. 2015; 132(18): 1726–1733 doi:https://doi.org/10.1161/CIRCULATIONAHA. . 115.015721.

Magee L, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;4:CD004351.

Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol. 2012;206:470–5. https://doi.org/10.1016/j.ajog.2011.09.002.CrossRefPubMed

Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24(2):104–10. https://doi.org/10.1038/jhh.2009.45.CrossRefPubMed

Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol. 1998;105(11):1177–84.PubMed

Shen M, Smith GN, Rodger M, White RR, Walker MC, Wen SW. Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One. 2017;12:e0175914.PubMedPubMedCentral

Chelsey LC. Blood pressure, edema and proteinuria in pregnancy.9 .Proposal for classification. Prog Clin Biol Res. 1976;7:249–68.

Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy. 2010;29:294–300. https://doi.org/10.3109/10641950902777747.CrossRefPubMed

10.

Kuklina EV, Tong X, Bansil P, George MG, Callaghan WM. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for concern? Stroke. 2011;42:2564–70. https://doi.org/10.1161/STROKEAHA.110.610592.CrossRefPubMed

11.

Maski AM, Baijracharva S, Wenger J, Zhang D, Salahuddin S. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation. 2015 November 3;132(18):1726–33. https://doi.org/10.1161/CIRCULATIONAHA.CrossRefPubMedPubMedCentral

12.

Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014;370:1307–1315. doi: https://doi.org/10.1056/NEJMoa1311485.

13.

Miller EC, Gatollari HJ, Too G, et al. Risk of pregnancy-associated stroke across age groups in New York State. JAMA Neurol. 2016;73(12):1461–7. https://doi.org/10.1001/jamaneurol.2016.3774.CrossRefPubMed

14.

Miller EC, Yaghi S, Boehme AK, Willey JZ, Elkind MS, Marshall RS. Mechanisms and outcomes of stroke during pregnancy and the postpartum period: a cross-sectional study. Neurol Clin Pract. 2016;6(1):29–39.PubMedPubMedCentral

15.

van Veen TR, Panerai RB, Haeri S, Griffioen AC, Zeeman GG, Belfort MA. Cerebral autoregulation in normal pregnancy and preeclampsia. Obstet Gynecol. 2013;122(5):1064–9.PubMed

16.

Hammer ES, Cipolla MJ. Cerebrovascular dysfunction in preeclamptic pregnancies. Curr Hypertens Rep. 2015;17(8):64.PubMedPubMedCentral

17.

Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014;130:1003–8.PubMed

18.

Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014;32:849–56.PubMed

19.

Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstet Gynaecol. 1987;94:1028–39.PubMed

20.

Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J. 1992;68:540–3.PubMedPubMedCentral

21.

Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013;20:209–14.PubMedPubMedCentral

22.

Berkane N, Liere P, Oudinet JP, Hertig A, Lefèvre G, Pluchino N, et al. From pregnancy to preeclampsia: a key role for estrogens. Endocr Rev. 2017;38(2):123–44.PubMed

23.

Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Phys Regul Integr Comp Phys. 2011;301(2):R267–75.

24.

. Kodogo V, Azibani F and Sliwa K. Role of pregnancy hormones and hormonal interaction on the maternal cardiovascular system: a literature review. Clin Res Cardiol. Epub ahead of print 26 February 2019. DOI: https://doi.org/10.1007/s00392-01901441-x

25.

Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol. 2011;31:15–32.PubMedPubMedCentral

26.

Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation. 2002;106:292–5.PubMed

27.

O’sullivan KP, Marshall SA, Cullen S, Saunders T, Hannan NJ, Senadheera SN, et al. Evidence of proteinuria, but no other characteristics of pre-eclampsia, in relaxin-deficient mice. Reprod Fertil Dev. 2017;29:1477–85. https://doi.org/10.1071/RD16056.CrossRefPubMed

28.

Marshall SA, Leo CH, Senadheera SN, Girling JE, Tare M, Parry LJ. Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice. Am J Physiol Regul Integr Comp. 2016a;310:R847–57. https://doi.org/10.1152/ajpregu.00506.2015Physiol.CrossRef

29.

Mirabito Colafella KM, Samuel CS, Denton KM. Relaxin contributes to the regulation of arterial pressure in adult female mice. Clin Sci. 2017;131:2795–805. https://doi.org/10.1042/CS20171225.CrossRef

30.

Gooi, J. H., Richardson, M. L., Jelinic, M., Girling, J. E., Wlodek, M. E., Tare, M., et al. (2013). Enhanced uterine artery stiffness in aged pregnant relaxin mutant mice is reversed with exogenous relaxin treatment. 89:18. Biol. Reprod doi: https://doi.org/10.1095/biolreprod.113.108118.

31.

Mirabito Colafella KM, Samuel CS, Denton KM. Relaxin contributes to the regulation of arterial pressure in adult female mice. Clin Sci. 2017;131:2795–805. https://doi.org/10.1042/CS20171225.CrossRef

32.

Lumbers ER, Pringle KG. Roles of the circulating renin angiotensin- aldosterone system in human pregnancy. Am J Phys Regul Integr Comp Phys. 2014;306(2):R91–R101.

33.

August P, Lindheimer MD. Pathophysiology of preeclampsia. Hypertension. 1995;142:2407–26.

34.

Chesley LC. Hypertensive disorders in pregnancy. New York: Appleton-Century-Crofts; 1978.

35.

Lindheimer MD, Katz AI. Renal physiology and disease in pregnancy. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. 2nd ed. New York: Raven Press; 1992. p. 3371–431.

36.

Granger JP, Alexander BT, Bennett WA, et al. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens. 2001;14:178S–85S.PubMed

37.

Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213(4 Suppl):S9.e1–S9–S11.

38.

Maloney KF, Heller D, Baergen RN. Types of maternal hypertensive disease and their association with pathologic lesions and clinical factors. Fetal Pediatr Pathol. 2012;31:319–23.PubMed

39.

Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58–e1–8.PubMed

40.

Ghuman N, Rhiener J, Tendler BE, White WB. Hypertension in the postpartum woman: clinical update for the hypertension specialist. J Clin Hypertens (Greenwich). 2009;11:726–33.

41.

Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol. 2004;190:577–8.PubMed

42.

Makkonen N, Harju M, Kirkinen P. Postpartum recovery after severe pre-eclampsia and HELLP-syndrome. J Perinat Med. 1996;24:641–9.PubMed

43.

Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol. 2009;114:1307–14.PubMed

44.

Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clin Exp Nephrol. 2008;12:102–9.PubMed

45.

Walters BNJ, Thompson ME, Lee A, de Swiet M. Blood pressure in the puerperium. Clin Sci (Colch). 1986;71:589–94.

46.

Ferrazzani S, De Carolis S, Pomini F, Testa AC, Mastromarino C, Caruso A. The duration of hypertension in the puerperium of preeclamptic women: relationship with renal impairment and week of delivery. Am J Obstet Gynecol. 1994;17:506–12.

47.

Clark SL, Belfort MA, Dildy GA, et al. Emergency department use during the postpartum period: implications for current management of the puerperium. Am J Obstet Gynecol. 2010;203:38–e1–6.PubMed

48.

Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum pre- eclampsia: an experience of 151 cases. Am J Obstet Gynecol. 2004;190:1464–6.PubMed

49.

Hargood JL, Brown MA. Pregnancy-induced hypertension: recurrence rate in second pregnancies. Med J Aust. 1991;154:376–7.PubMed

50.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122:478–87.PubMed

51.

Silver HM, Seebeck M, Carlson R. Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes. Am J Obstet Gynecol. 1998;179:87–93.PubMed

52.

Ohashi Y, Ibrahim H, Furtado L, Kingdom J, Carvalho JC. Non-invasive hemodynamic assessment of non-pregnant, healthy pregnant and preeclamptic women using bioreactance. [corrected]. Rev Bras Anestesiol. 2010;60:603–13 335–40.PubMed

53.

Ditisheim A, Wuerzner G, Ponte B, Vial Y, Irion O, Burnier M, et al. Prevalence of hypertensive phenotypes after preeclampsia: a prospective cohort study. Hypertension. 2018;71:103–9.PubMed

54.

Martillotti G, Ditisheim A, Burnier M, Wagner G, Boulvain M, Irion O, et al. Increased salt sensitivity of ambulatory blood pressure in women with a history of severe preeclampsia. Hypertension. 2013;62:802–8. https://doi.org/10.1161/HYPERTENSIONAHA.113.01916.CrossRefPubMed

55.

Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37(2 pt 2):429–32.PubMed

56.

Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734–7. https://doi.org/10.1016/S0140-6736(97)05189-1.CrossRefPubMed

57.

Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis. 1999;33:29–35.PubMed

58.

Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers E, Roeters van Lennep J Blood pressure profile 1 year after severe preeclampsia. Hypertension. 2018 Mar;71(3):491–498. doi: https://doi.org/10.1161/HYPERTENSIONAHA.117.10338.

59.

Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis. 1994;24:883–7.PubMed

60.

Tan L-K, De Swiet M. The management of postpartum hypertension. BJOG Int J Obstet Gynaecol. 2002;109:733–6. https://doi.org/10.1111/j.1471-0528.2002.01012.x.CrossRef

61.

Stagnaro-Green A. Postpartum thyroiditis. J Clin Endocrinol Metab. 2002;87:4042–7.PubMed

62.

Wuytack F, Smith V, Cleary BJ. Oral non-steroidal anti-inflammatory drugs (single dose) for perineal pain in the early postpartum period. The Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.:CD011352.

63.

Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011;19:184–91.PubMed

64.

Johnson AG, Nguen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289–300.PubMed

65.

Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–226.PubMed

66.

Palmer BF. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Investig Med. 1995;43:516–33.PubMed

67.

Executive summary: hypertension in pregnancy. American College of Obstreticians and Gynecologists. Obstet Gynecol 2013;122:1122–1131, Hypertension in Pregnancy.

68.

Oscar A, Viteri MD, Joey A, England MD, Mesk A, Alrais MD, et al. Association of nonsteroidal antiinflammatory drugs and postpartum hypertension in women with preeclampsia with severe fatures. Obstet Gynecol. 2017;130(4):830–5.

69.

Blue NR, Murray-Krezan C, Drake-Lavelle S, Weinberg D, Holbrook BD, Katukuri VR, et al. Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. Am J Obstet Gynecol. 2018;218(6):616–e1–616.e8.PubMedPubMedCentral

70.

Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.PubMedPubMedCentral

71.

Felder RA, White MJ, Williams SM, Jose PA. Diagnostic tools for hypertension and salt sensitivity testing. Curr Opin Nephrol Hypertens. 2013;22:65–76.PubMedPubMedCentral

72.

Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47:1168–74.PubMed

73.

Vikse B, Irgens L, Leivestad T, Skjaerven R, Iversen B. Pre-eclampsia and the risk of end-stage kidney disease. N Engl J Med. 2008;359:800–9.PubMed

74.

Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension. 2010;55:1239–45.PubMed

75.

Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH. Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks’ gestation and preeclampsia: a case-control study. J Hum Hypertens. 2013;27:38–43.PubMed

76.

Walters BNJ, Thompson ME, Lee A, de Swiet M. Blood pressure in the puerperium. Clin Sci. 1986;71:589–94.

77.

Därr R, Lenders JW, Hofbauer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab. 2012;3(1):11–26. https://doi.org/10.1177/2042018812437356.CrossRefPubMedPubMedCentral

78.

Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27(Suppl):S49–54.PubMed

79.

Kelsey, Julie J.. “Drug principles in lactation.” (2016).

80.

American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.

81.

Magee LA, Miremadi S, Li J, Cheng C, Ensom M, Carleton B, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 193(1):153–63.

82.

O’Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229–38.PubMed

83.

Burnier M, Phan O, Wang Q. High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol Dial Transplant. 2007;22:2426–9.PubMed

84.

Aoki H, Ito N, Kaniwa N, Saito Y, Wada Y, Nakajima K, et al. Low levels of amlodipine in breast milk and plasma. Breastfeed Med. 2018 Nov;13(9):622–6. https://doi.org/10.1089/bfm.2018.0158Epub 2018 Sep 28.

85.

Liedholm H, Melander A, Bitzen PO, Lonnerholm G, Mattiasson I, Wilsson B, et al. Accumulation of atenolol and metoprolol in human breast. Milk.Eur J Clin Pharmacol. 1981;20:229–31.

86.

Shannon ME, Malecha SE, Cha AJ. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update. J Hum Lact. 2000;16:152–5.PubMed

87.

Healy M. Suppressing lactation with oral diuretics. Lancet. 1961;277:1353–4.

88.

Vigil-de Gracia P, Ruiz E, Lσpez JC, et al. Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial. Hypertens Preg nancy. 2007;26:163–71.

89.

Vermillion ST, Scardo JA, Newman RB, Chauhan SP Chauhan SP.A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol 1999;181:858–861.

90.

Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119:78–85.PubMed

91.

Sharma KJ, Greene N, Kilpatrick SJ. Oral labetalol compared to oral nifedipine for postpartum hypertension: a randomized controlled trial. Hypertension in Pregnancy. 2017;36(1):44–7. https://doi.org/10.1080/10641955.2016.1231317.CrossRefPubMed

92.

Vigil-de Gracia P, Ludmir J. The use of magnesium sulfate for women with severe preeclampsia or eclampsia diagnosed during the postpartum period. J Matern Fetal Neonatal Med. 2015;28:2207–9.PubMed

93.

Vigil-De Gracia P, Ramirez R, Durán Y, Quintero A. Magnesium sulfate for 6 vs 24 hours post delivery in patients who received magnesium sulfate for less than 8 hours before birth: a randomized clinical trial. BMC Pregnancy Childbirth. 2017;17(1):241. Published 2017 Jul 24. doi:https://doi.org/10.1186/s12884-017-1424-3

Titel: Postpartum Hypertension
verfasst von: V. Katsi
G. Skalis
G. Vamvakou
D. Tousoulis
T. Makris
Publikationsdatum: 01.08.2020
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 8/2020
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-020-01058-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Weight Reduction for Obesity-Induced Heart Failure with Preserved Ejection Fraction

Correction to: Maternal Hypertension, Advanced Doppler Haemodynamics and Therapeutic Precision: Principles and Illustrative Cases

Bariatric Surgery for Resistant Hypertension: Working in Progress!

Vitamin D and Arterial Hypertension: Facts and Myths

Benefits of Community-Based Approaches in Assessing and Addressing Sleep Health and Sleep-Related Cardiovascular Disease Risk: a Precision and Personalized Population Health Approach